1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

DelveInsight’s, “ Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global Market therapeutics scenario for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- A review of the marketed products under prescription for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
- Coverage of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.
- API intelligence over marketed drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information

List of Tables
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers, Global, 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2014

List of Figures
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2014
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Related Market Segments :

Hormone

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.